文献速递胸部肿瘤

抑制DSTYK使非小细胞肺癌对紫杉烷类化疗增敏

DSTYK Inhibition Sensitizes NSCLC to Taxane-Based Chemotherapy.
PubMed 文献 · J Thorac Oncol · 2024-11-12

研究探索DSTYK在肺癌化疗耐药中的作用,利用细胞系数据、两个患者队列及体内外实验,发现DSTYK缺失特异增敏紫杉烷类化疗,DSTYK扩增与紫杉烷耐药强相关,可能作为耐药预测标志和可干预靶点。

要点

  • DSTYK缺失特异增敏肺癌细胞对紫杉烷类化疗,尤其联合卡铂。
  • 新辅助和辅助队列中DSTYK扩增与紫杉烷耐药强相关。
  • DSTYK扩增可能是紫杉烷治疗耐药的预测因子和可干预靶点。

核心结论

  • DSTYK扩增可能是紫杉烷类治疗耐药的预测因子,并代表这些患者的可干预靶点。

研究设计与样本

  • 利用Depmap泛癌细胞系DSTYK拷贝数数据进行紫杉醇、卡铂、培美曲塞和顺铂敏感性分析。
  • 辅助队列为来自VHIO的IV期肺腺癌患者,一线接受卡铂联合紫杉醇或卡铂联合培美曲塞治疗。
  • 新辅助队列包括NADIM I和NADIM II临床试验中可切除IIIA或IIIB期NSCLC患者的肿瘤样本,围手术期接受纳武利尤单抗联合化疗(卡铂+紫杉醇)。
  • DSTYK拷贝数通过荧光原位杂交和定量逆转录聚合酶链反应评估。
  • 进行蛋白质组学和生物信息学分析研究差异表达蛋白特征。

主要发现

  • DSTYK耗竭特异增敏肺癌细胞对紫杉烷类化疗,尤其联合卡铂。
  • DSTYK消融重塑细胞骨架,并在体内损害远处侵袭和转移生长。
  • DSTYK下调使原发和转移性肺肿瘤对化疗免疫治疗增敏,导致小鼠模型肿瘤消退。
  • 早期和晚期肺癌患者临床数据(新辅助和辅助设置)显示DSTYK扩增与紫杉烷耐药强相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chemotherapy continues to be the standard treatment for patients noneligible for targeted or immune-based therapies; nevertheless, treatment resistance remains a major clinical challenge. We previously found that expression levels of DSTYK, a poorly explored dual serine/threonine and tyrosine kinase frequently amplified in cancer, identified patients with lung cancer exhibiting poor response to immune checkpoint inhibitors, and found that its inhibition sensitizes to immunotherapy. Seeking to explore the potential of DSTYK targeting in additional indications, we investigated the functional relevance and actionability of DSTYK in lung cancer chemoresistance. METHODS: In silico analysis to study the differential sensitivity to paclitaxel, carboplatin, pemetrexed, and cisplatin drugs was performed using pan-cancer human cancer cell line DSTYK CN data downloaded from Depmap portal (https://depmap.org/portal/depmap/). Two cohorts of patients with lung cancer were used. An adjuvant cohort composed of patients with advanced IV-stage lung adenocarcinoma treated with carboplatin plus paclitaxel or carboplatin plus pemetrexed in the first line from VHIO; A neoadjuvant cohort including resectable stage IIIA or IIIB NSCLC tumor samples of patients from NADIM I and NADIM II clinical trials perioperative treated with nivolumab plus chemotherapy (carboplatin + paclitaxel). DSTYK CN was assessed by fluorescence in situ hybridization and quantitative reverse transcription-polymerase chain reaction. Proteomics and bioinformatic analyses were performed to study differentially expressed protein signatures. Functional in vitro experiments (adhesion, migration, and invasion) in both murine and human systems, and in vivo lung orthotopic, intracardiac, and intratibial xenograft and syngeneic models complete the study. RESULTS: We show that DSTYK depletion specifically sensitizes lung cancer cells to taxane-based chemotherapy, particularly in combination with carboplatin. Mechanistically, DSTYK ablation remodels the cytoskeleton and impairs distant invasion and metastatic outgrowth in vivo. DSTYK downregulation sensitizes both primary and metastatic lung tumors to chemoimmunotherapy treatment leading to tumor regression in mouse models. Consistently, clinical data of patients with early and advanced lung cancer-in the neoadjuvant and adjuvant settings-show a strong correlation between DSTYK amplification and taxane resistance, underscoring the clinical significance of our findings to inform treatment decision-making. CONCLUSIONS: Collectively, our data indicates that DSTYK amplification may be a predictor of resistance to taxane-based treatments and represents an actionable target for these patients.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Echepare M, Picabea B, Arricibita A, et al. DSTYK Inhibition Sensitizes NSCLC to Taxane-Based Chemotherapy. J Thorac Oncol. 2024. PMID: 39536877. doi:10.1016/j.jtho.2024.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。